The Lynx Group
Cholangiocarcinoma News

Improving Chemotherapy Combinations and Novel Treatments Are Needed in Advanced Biliary Tract Cancer

December 2020, Vol 1, No 3

New cytotoxic chemotherapy regimens and novel combinations are being evaluated in clinical trials in an effort to improve the outcomes of chemotherapy in the adjuvant and palliative settings in patients with biliary tract cancer, including cholangiocarcinoma (CCA), said Angela Lamarca, MD, PhD, MSc, Consultant, Medical Oncology, the Christie NHS Foundation Trust, Manchester, United Kingdom. She discussed the future of cytotoxic chemotherapy for this patient population at the 2020 Cholangiocarcinoma Summit.

In the adjuvant setting, the current gold standard for the treatment of patients with CCA is capecitabine. Developing more effective cytotoxic chemotherapy regimens are needed, because not all patients have adequate tissue for molecular profiling that would allow selection of targeted therapy, she said.

“Almost 1 of every 4 patients [with CCA] that were referred for molecular profiling didn’t have enough tissue in that biopsy,” Dr Lamarca explained. “The second problem we are facing is that even for those patients where we do have enough tissue from molecular profiling, around 60% of them will not have a targetable finding. Therefore, we need better options for this 60% of patients with CCA,” she said.

The ACTICCA 1 study is a multicenter, prospective, randomized phase 3 clinical trial designed to compare the efficacy and safety of adjuvant gemcitabine plus cisplatin versus capecitabine after resection of CCA and muscle-invasive gallbladder cancer.

“Until we have the results, capecitabine remains the standard of care,” said Dr Lamarca.

Triple-Drug Combinations

Triple-drug chemotherapy with gemcitabine, cisplatin, and S1 (an oral fluoropyrimidine prodrug) improved median progression-free survival versus gemcitabine plus cisplatin alone (7.4 vs 5.5 months, respectively) and overall survival (13.5 vs 12.6 months, respectively) in a randomized phase 3 clinical trial of patients with advanced biliary tract cancer.

Nevertheless, these benefits may not be enough to justify the added toxicity of S1, Dr Lamarca noted. Still, the higher response rate with the triplet regimen (41.5%) than with the doublet therapy (15%) may make the triplet regimen beneficial in the neoadjuvant setting or for patients with locally advanced disease.

“Not all the triple combinations have been successful,” Dr Lamarca pointed out. For example, a modified FOLFIRINOX regimen did not improve progression-free survival versus cisplatin and gemcitabine in patients with advanced biliary tract cancer.

Novel Approaches

Approximately 17% of patients with biliary tract cancer have a DNA damage repair (DDR) gene mutation, indicating a potential role for platinum-based chemotherapy in this patient population. Although some studies report longer survival with such regimens in patients with DDR mutations, others do not.

The investigational compound NUC-1031 is designed to overcome key resistance mechanisms to gemcitabine, resulting in increased intracellular levels of the anticancer metabolite gemcitabine triphosphate. In a phase 1b study, the combination of NUC-1031 and cisplatin as first-line therapy for advanced biliary tract cancer led to responses in 4 patients, including 3 partial responses, among 8 patients with locally advanced or metastatic disease. A phase 3 study of NUC-1031 plus cisplatin versus cisplatin plus gemcitabine is underway.

Novel treatment targets that have been identified in biliary tract cancer, mainly in patients with intrahepatic CCA, include fusion proteins. Fusion proteins are likely oncogenic drivers, because the use of tyrosine kinase inhibitors (TKIs) has induced clinically meaningful responses in patients with intrahepatic CCA harboring FGFR2 fusions.

Although immunotherapy monotherapy for the treatment of CCA has shown disappointing results, combining immunotherapy with chemotherapy has resulted in response rates superior to those obtained with immunotherapy alone, said Dr Lamarca.

“Because of that, there are at least 3 randomized phase 3 clinical trials in the first-line setting combining immunotherapy compounds with gemcitabine, and comparing the outcomes to cisplatin and gemcitabine alone,” Dr Lamarca pointed out.

Finally, combining immunotherapy with TKIs is a rational strategy that has shown promising early results in patients with advanced biliary tract cancer. Combinations with early data to support their efficacy include the combination of immunotherapy with the PD-1 inhibitor toripalimab plus the multikinase inhibitor lenvatinib (Lenvima) and oxaliplatin plus gemcitabine, as well as the combination of the TKI imatinib (Gleevec) plus the PD-1 inhibitor pembrolizumab (Keytruda).

Related Items

Targeted Therapies in Cholangiocarcinoma: Next-Generation Sequencing Is a Must
December 2020, Vol 1, No 3
The recent FDA approval of the first FGFR inhibitor, pemigatinib (Pemazyre), and the positive results from the phase 3 study of the first IDH1 inhibitor, ivosidenib (Tibsovo), represent major breakthroughs in the treatment of patients with cholangiocarcinoma (CCA), a rare cancer associated with poor outcomes. However, the duration of response with these agents is still relatively short.
Gallbladder Cancer: Novel Approaches to Therapy Are Needed
December 2020, Vol 1, No 3
The current standard of care for the systemic treatment of patients with advanced gallbladder cancer is the chemotherapy combination of gemcitabine and cisplatin, which is suboptimal, yielding only modest benefit, said Richard Kim, MD, Section Chief, Gastrointestinal Medical Oncology, Moffitt Cancer Center, Tampa, FL, at the 2020 Cholangiocarcinoma Summit.
FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
December 2020, Vol 1, No 3
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).
Role of Liver Transplant in Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Liver transplant is emerging as a treatment option in patients with unresectable hilar or intrahepatic cholangiocarcinoma (CCA), with accumulating data supporting transplant protocols in patients with early-stage CCA.
The Oncology Pipeline Offers Hope for Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Despite the onslaught of the COVID-19 pandemic, researchers are hard at work to develop innovative therapies that will make a difference in the lives of patients with cancer.
Genomic Testing in Cholangiocarcinoma: Look for Actionable Molecular Alterations
December 2020, Vol 1, No 3
At the 2020 Cholangiocarcinoma Summit, Nabeel El-Bardeesy, PhD, Associate Professor, Medicine, Harvard Medical School, and Associate Geneticist, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, moderated a session titled “Molecular Biomarkers in CCA: Focus on Current and Emerging Technologies.” The session focused on how best to integrate the array of genomic testing platforms into clinical practice. The session included 2 presenters who discussed this topic.
Zanidatamab Addresses an Unmet Need in Patients with HER2-Amplified Biliary Tract Cancer
December 2020, Vol 1, No 3
Patients with relapsed or refractory HER2-amplified biliary tract cancer have few treatment options after first-line therapy. Shubham Pant, MD, Associate Professor, Gastrointestinal Oncology, M.D. Anderson Cancer Center, Houston, TX, presented the results of a phase 1 clinical trial he and his colleagues conducted. The study examined the safety and antitumor activity of zanidatamab, a bispecific (ie, binding to 2 distinct sites on the HER2 receptor) HER2-targeted antibody. The unique antibody geometry of zanidatamab enables it to activate several mechanisms of action after binding to the HER2 receptor.
Increasing Number of Biomarkers Being Studied in Cholangiocarcinoma Clinical Trials
December 2020, Vol 1, No 3
At diagnosis, the majority of patients with intrahepatic cholangiocarcinoma (CCA) present with advanced disease and a poor prognosis. Comprehensive genomic profiling (CGP) of intrahepatic CCA has revealed multiple potential therapeutic targets, including FGFR2, ERBB2 (HER2), and IDH1. Therefore, performing CGP early in the disease course is critical to increasing first-line clinical trial enrollment and access to treatment with FGFR inhibitors.
Telotristat Ethyl and First-Line Chemotherapy Combination Investigated for Advanced Biliary Tract Cancer
December 2020, Vol 1, No 3
The metabolism of serotonin is dysregulated in cholangiocarcinoma (CCA) cell lines compared with normal cholangiocytes and in tissue and bile from patients with CCA.1 Telotristat ethyl (Xermelo) is a tryptophan hydroxylase inhibitor that is indicated for the treatment of patients with carcinoid syndrome–related diarrhea not well-controlled by somatostatin analog. Telotristat ethyl is currently being investigated for the treatment of patients with biliary tract cancer, including CCA tumors that express serotonin.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: